A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
DISEASE(S): Unresectable Or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2760783 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA